Nvidia's China restart faces production obstacles: Report
Nvidia said this week that it was planning to resume sales of the H20 chips to China, though under the policy change the U.S. must still approve licenses for the export of the chips.
The U.S. government's April ban on sales of the H20 chips had forced Nvidia to void customer orders and cancel manufacturing capacity it had booked at chipmaker Taiwan Semiconductor Manufacturing (TSMC), said the report in tech publication The Information, citing two people with knowledge of the matter.
TSMC had shifted its H20 production lines to produce other chips for other customers, and manufacturing new chips from scratch could take nine months, Nvidia CEO Jensen Huang said at a media event in Beijing this week, according to the report.
The report also said Nvidia did not plan to restart production, without citing any sources or giving details.
Nvidia declined to comment on the report. Reuters could not immediately verify the report.
Huang made comments in recent days suggesting Nvidia would ramp up supply of H20 chips, and that licenses for Chinese orders would be approved swiftly.
Nvidia has also announced that it is developing a new chip for Chinese clients called the RTX Pro GPU, which would be compliant with U.S. export restrictions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
39 minutes ago
- Business Standard
Mukul Agrawal portfolio stock up 87% from April; what's behind the rally?
Tatva Chintan Pharma Chem share price today Shares of Tatva Chintan Pharma Chem hit a 52-week high of ₹1,139, as they surged 12 per cent on the BSE in Friday's intra-day trade in an otherwise weak market. A sharp surge in stock price after the company reported healthy earnings for the quarter ended June 2025 (Q1FY26). The stock price of the smallcap specialty chemicals surpassed its previous high of ₹1,101.40 touched on September 25, 2024. It has zoomed by 87 per cent from its 52-week low of ₹610 hit on April 7, 2025. At 09:40 AM; Tatva Chintan Pharma Chem was trading 10 per cent higher at ₹1,119.15, as compared to 0.35 per cent decline in the BSE Sensex. Q1 results - Tatva Chintan Pharma Chem For the April to June 2025 quarter (Q1FY26), Tatva Chintan Pharma Chem reported 33.7 per cent year-on-year (YoY) jump in consolidated profit after tax at ₹6.65 crore. Revenue from operations grew 10.8 per cent at ₹116.86 crore. Earnings before interest, taxes, depreciation, and amortization (EBITDA) grew 37.4 per cent YoY at ₹17.33 crore; margins improvement 280 bps at 14.8 per cent. The company manufactures Structure Directing Agents (SDA), Phase Transfer Catalysts, Electrolyte Salts for Super Capacitor Batteries and Pharma & Agro Intermediates and Specialty Chemicals. Trends in specialty chemicals landscape The Indian chemical industry got advantage vs China due to Trust deficit between China and the US; stringent environmental regulations since 2015 and large-scale shutdowns in China; customers preference to de-risk the supply chain led to China+1 policy; geopolitical shift after the outbreak of Covid-19 and increased cost of labour. With an increasing awareness of the ill effects of certain chemicals on humans and the environment, there is a growing trend in the chemicals industry to shift towards what is known as 'green' chemicals or more accurately sustainable chemistry. Meanwhile, China holds 39% share in the global chemical industry of which exportable specialty chemicals accounts for ~15-17 per cent while India accounts for merely 1-2 per cent indicating widespread opportunity. The spillover impact of China's declining competitiveness has set the stage for India to intensify its effort to capture larger market share, the company said. Meanwhile, during FY 25, one of the major products of the company SDA (Structure Directing Agents) saw moderation in offtake from its major export destination which is China. Due to higher adoption of LNG Powered trucks by Chinese companies, the company saw substantial decline in SDA demand from Chinese consumers. Further, the Group will be entering into the commercial phase of new products in FY 26 and offtake of new products will be crucial for improvement of business risk profile, Crisil Ratings said in its rationale. Mukul Mahavir Agrawal holds over 1 per cent holding in Tatva Chintan Pharma Chem Investor Mukul Mahavir Agrawal held 300,000 equity shares or 1.28 per cent stake in Tatva Chintan Pharma Chem at the end of June 2025 quarter, the shareholding pattern data shows. Mukul Agrawal held NIL or less than 1 per cent holding in the company at the end of March 2025 quarter, the data shows. According to information available, Mukul Mahavir Agrawal holds over 1 per cent stake in other notable listed companies, including BSE, Neuland Laboratories, Radico Khaitan, Nuvama Wealth Management, PTC Industries and LT Foods.
News18
an hour ago
- News18
India flexible on Chinese investments in electronics: Govt source
New Delhi, Jul 25 (PTI) India is flexible for collaboration of domestic companies with Chinese, especially electronics, a government source said on Friday. Around 60 per cent of electronics manufacturing happens in China, and hence, it is not easy to ignore it, the source added. 'Things are easing (between India and China). There are signals. Tourist visas have been opened. In electronics, 60 per cent of manufacturing takes place in China. So, there has to be some sort of collaboration," the sources said. He was replying to a question on government approval for the Dixon joint venture with Chinese companies. Dixon Technologies has received approval from the Indian government to form a joint venture (JV) with Chinese peer Longcheer. Dixon has been reaching out to several Chinese companies for joint ventures. It has signed separate agreements with Chinese electronic component firms — Chongqing Yuhai Precision Manufacturing Co Ltd and the Indian arm of Kunshan Q Technology — for manufacturing and sales of electronic components used in electronic devices like mobile phones and laptops, among others. First Published: July 25, 2025, 13:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
India.com
an hour ago
- India.com
Bad news for employees of this company as it plans to lay off over 24000 workers due to…, not TCS, Infosys, Apple, Amazon, Google, Microsoft, it is…
In today's technology landscape, massive layoffs have become normalized. Several high-profile tech companies are letting go of thousands of employees, not for performance reasons but as part of company-wide restructuring. Companies from small startups to large global organizations are restructuring their workforce to save costs, implement new technologies, or reorganize for a rapidly changing technology setting. Now, Intel, one of the world's largest chipmaking companies, plans to lay off around 24,000 employees this year. Yes, you heard it right. According to the TimesOfIndia report, Intel will lay off roughly 24000 employees this year, which is about 1/4 of the employees of Intel. The new CEO, Lip-Bu Tan, is making significant changes in order to cut costs and improve the company. As part of that process, Intel has also scrapped plans to expand into Germany and Poland. The semiconductor titan employed 99,500 core workers at the end of 2024. But now, it plans to drop that number to only 75,000 total employees by the end of 2025. CEO Lip-Bu Tan called these cuts 'hard but necessary decisions' in a memo shared with the company's employees on Thursday. In the memo on July 24, 2025, Tan stated in the memo,' I know the past few months have not been easy. We are making hard but necessary decisions to streamline the organization, drive greater efficiency and increase accountability at every level of the company.' The job cuts include layoffs already in the second quarter, in which Intel removed about half of its layers, and was a restructuring with a $1.9 billion in total costs. While writing to the employees, Tan stated, 'There are no more blank checks. Every investment must make economic sense.' The company reported a net loss of USD 2.9 billion, which included restructuring-related costs associated with the most recent layoff. Revenue for the quarter was flat USD 12.9 billion, still above the expectations of the market. This marks the longest period of time in 35 years that the company has lost money, with six quarters in a row. Even after the company generated more money than Wall Street was anticipating, Intel continues to fall further behind competitors in the rapidly growing AI business, especially Nvidia and AMD.
